Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity
of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in
Subjects with myelodysplastic syndrome after treatment with hypomethylating agents